Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Hematology

Standard Treatments and Emergency Care for ITP

At a Glance

The goal of ITP treatment is to maintain a safe platelet count to prevent severe bleeding, rather than achieving a completely normal count. Approaches range from observation in children to first-line steroids, second-line platelet-boosting medications, and emergency therapy for acute bleeds.

Managing ITP is a journey that often evolves over time. The goal of treatment is not necessarily to achieve a “normal” platelet count (150,000+), but rather to maintain a safe platelet count—usually above 20,000 to 30,000—that prevents serious bleeding and allows for a high quality of life [1][2].

Pediatric vs. Adult Approaches

The first decision in treatment depends heavily on the patient’s age:

  • For Children: Because pediatric ITP often resolves on its own, doctors frequently recommend a “watch and wait” strategy [3]. If the child has only bruising or petechiae (skin signs) and no active bleeding, doctors may simply observe them closely rather than using drugs that might have side effects [4].
  • For Adults: Adults are less likely to have a spontaneous recovery. Therefore, treatment is more common, especially if the count is very low or there are signs of bleeding [1].

First-Line Treatments (The First Step)

These are the standard treatments used when ITP is newly diagnosed:

  • Corticosteroids: These oral drugs (like prednisone or dexamethasone pills) dampen the immune system’s attack on platelets [1]. They are effective but can cause mood changes, weight gain, and high blood sugar. Crucially, corticosteroids cannot be stopped abruptly. They must be slowly “tapered” down under a doctor’s supervision to prevent severe withdrawals.
  • IVIG (Intravenous Immunoglobulin): This is an IV infusion of concentrated antibodies that “distracts” the immune system, providing a rapid but temporary boost in platelets [5][6].
  • Anti-D (WinRho): Another IV infusion option for certain patients (those who are Rh-positive and still have their spleen). Like IVIG, it provides a temporary increase in platelets [1].

Second-Line Treatments (Long-Term Management)

If first-line treatments don’t work, or if steroids need to be stopped due to side effects, doctors move to second-line options. Modern guidelines recommend exhausting these medications before considering irreversible surgery [1][7].

  1. TPO-RAs (Thrombopoietin Receptor Agonists): These drugs stimulate the bone marrow to produce more platelets [8]. They are taken either as a daily oral pill (like eltrombopag or avatrombopag) or a weekly subcutaneous injection (like romiplostim).
  2. Rituximab: This is a targeted therapy given as a series of IV infusions over a few weeks. It removes the B-cells responsible for making the autoantibodies that attack platelets [9].
  3. Fostamatinib: A newer, daily oral pill that blocks the specific signaling pathway used by the body to destroy platelets [10][11].
  4. Splenectomy (Surgery): Surgery to remove the spleen. Because the spleen is the main site of platelet destruction, removing it can lead to long-term remission [12]. However, this is usually considered a “last resort” further down the line, as it carries a lifelong risk of infection and blood clots [13][14].

Emergency Management

In rare cases of life-threatening bleeding (like a brain or severe stomach bleed), doctors use a combination therapy approach. This involves giving high-dose IV steroids, IVIG, and often platelet transfusions all at once in the hospital to raise the count as fast as possible [6][1].

Always discuss the benefits, risks, and administration methods of each tier with your hematologist to find the path that best fits your life [9].

Return to the Home Page.

Common questions in this guide

Is treatment always necessary for children with ITP?
No, many pediatric ITP cases resolve on their own. Doctors often recommend a "watch and wait" approach for children who only have skin signs like bruising or petechiae and no active bleeding, to avoid unnecessary drug side effects.
What is considered a safe platelet count for someone with ITP?
The goal of ITP treatment is usually not to reach a normal count of over 150,000, but rather to maintain a safe platelet count above 20,000 to 30,000. This level is generally sufficient to prevent serious bleeding and allow for a high quality of life.
What are the first-line treatments for newly diagnosed ITP?
Standard first-line treatments include oral corticosteroids like prednisone, Intravenous Immunoglobulin (IVIG), and Anti-D infusions. These medications work by either dampening the immune system's attack on platelets or temporarily distracting it to boost platelet levels.
Why do I need to slowly taper off my corticosteroids?
Corticosteroids like prednisone and dexamethasone cannot be stopped abruptly because doing so can cause severe withdrawal symptoms. They must be slowly tapered down under a doctor's careful supervision.
What happens if first-line ITP treatments do not work?
If initial treatments fail or cause severe side effects, hematologists will typically move to second-line options. These include TPO-RA medications to stimulate platelet production, targeted therapies like Rituximab, or newer oral medications like Fostamatinib.
Is removing the spleen a recommended treatment for ITP?
Surgical removal of the spleen can lead to long-term remission since the spleen is the main site of platelet destruction. However, it is usually considered a last resort because it carries a lifelong risk of infection and blood clots.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my (or my child's) current count and symptom level appropriate for a 'watch and wait' approach?
  2. 2.What is the 'safe' platelet count we are aiming for in my specific case, rather than just a 'normal' count?
  3. 3.What is the specific timeline and protocol for safely tapering off my corticosteroids?
  4. 4.If we move to second-line treatment, which option (pills, injections, or IV infusions) aligns best with my lifestyle and risk tolerance?
  5. 5.What is our plan for emergency management if I (or my child) experience a sudden, severe bleed?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives.

    Zitek T, Weber L, Pinzon D, Warren N

    Open access emergency medicine : OAEM 2022; (14()):25-34 doi:10.2147/OAEM.S331675.

    PMID: 35125895
  2. 2

    Proposal of treatment algorithm for immune thromocytopenia in adult patients of a hematology service at a referral center in Northeastern Brazil.

    Ribeiro RA, Galiza Neto GC, Furtado ADS, et al.

    Hematology, transfusion and cell therapy 2019; (41(3)):253-261 doi:10.1016/j.htct.2018.10.005.

    PMID: 31085155
  3. 3

    Multicenter Cohort Study Comparing U.S. Management of Inpatient Pediatric Immune Thrombocytopenia to Current Treatment Guidelines.

    Witmer CM, Lambert MP, O'Brien SH, Neunert C

    Pediatric blood & cancer 2016; (63(7)):1227-31 doi:10.1002/pbc.25961.

    PMID: 26929009
  4. 4

    Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions.

    Bergmann S

    Clinical case reports 2017; (5(10)):1660-1663 doi:10.1002/ccr3.1086.

    PMID: 29026567
  5. 5

    Outcome and response to different management regimens in pediatric patients with immune thrombocytopenia (ITP).

    AbdelAziz RA, El-Sayed D, Ahmed FEZ, Komy MA

    Annals of hematology 2025; (104(10)):5003-5010 doi:10.1007/s00277-025-06626-1.

    PMID: 41003735
  6. 6

    Bleeding complications in immune thrombocytopenia.

    Arnold DM

    Hematology. American Society of Hematology. Education Program 2015; (2015()):237-42 doi:10.1182/asheducation-2015.1.237.

    PMID: 26637728
  7. 7

    Updated guidelines for immune thrombocytopenic purpura: Expanded management options.

    DeSouza S, Angelini D

    Cleveland Clinic journal of medicine 2021; (88(12)):664-668 doi:10.3949/ccjm.88a.20201.

    PMID: 34857604
  8. 8

    Treatment of primary and secondary immune thrombocytopenia.

    Kado R, McCune WJ

    Current opinion in rheumatology 2019; (31(3)):213-222 doi:10.1097/BOR.0000000000000599.

    PMID: 30920453
  9. 9

    Management of immune thrombocytopenia: 2022 update of Korean experts recommendations.

    Park YH, Kim DY, Kim S, et al.

    Blood research 2022; (57(1)):20-28 doi:10.5045/br.2022.2022043.

    PMID: 35342042
  10. 10

    Fostamatinib for the treatment of chronic immune thrombocytopenia.

    Connell NT, Berliner N

    Blood 2019; (133(19)):2027-2030 doi:10.1182/blood-2018-11-852491.

    PMID: 30803989
  11. 11

    Fostamatinib for the treatment of immune thrombocytopenia in adults.

    Moore DC, Gebru T, Muslimani A

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2019; (76(11)):789-794 doi:10.1093/ajhp/zxz052.

    PMID: 30951590
  12. 12

    Sequence of Splenectomy and Rituximab for the Treatment of Steroid-Refractory Immune Thrombocytopenia: Does It Matter?

    Hammond WA, Vishnu P, Rodriguez EM, et al.

    Mayo Clinic proceedings 2019; (94(11)):2199-2208 doi:10.1016/j.mayocp.2019.05.024.

    PMID: 31685150
  13. 13

    Medical complications following splenectomy.

    Buzelé R, Barbier L, Sauvanet A, Fantin B

    Journal of visceral surgery 2016; (153(4)):277-86.

    PMID: 27289254
  14. 14

    Splenectomy is associated with a higher risk for venous thromboembolism: A prospective cohort study.

    Lee DH, Barmparas G, Fierro N, et al.

    International journal of surgery (London, England) 2015; (24(Pt A)):27-32.

    PMID: 26493210

This page provides educational information about ITP treatment options and is not a substitute for professional medical advice. Always consult your hematologist to determine the safest and most effective treatment plan for your specific platelet count and symptoms.

Get notified when new evidence is published on Immune thrombocytopenia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.